REGiMMUNE ^None

REGiMMUNE is a biopharmaceutical company that focuses on developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. They use their proprietary technology platform, reVax, to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells. Their technology has potential applications in immune system disorders such as Graft versus Host Disease, type 1 diabetes mellitus, rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. The company has one clinical-stage compound in a Phase I/II trial in the United States as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development as a new treatment for T1DM. They aim to reduce or eliminate significant side effects associated with long-term administration of conventional immunosuppressants.